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OBJECTIVE: Our study was a randomized, controlled trial to
assess a novel strategy that provides comprehensive colo-
rectal cancer screening in a single visitversustraditional
sigmoidoscopy and, where appropriate, colonoscopy on a
subsequent day.
METHODS: Consecutive patients referred for screening were
randomized to control or so-called “conversion” groups.
Patients in the control group were prepared for sigmoidos-
copy with oral phospho-soda. Those with an abnormal sig-
moidoscopy were scheduled for colonoscopy on a future
day after oral polyethylene glycol preparation. In the con-
version group, patients were prepared with oral phospho-
soda. Patients with a polyp.5 mm or multiple diminutive
polyps were converted from sigmoidoscopy to colonoscopy,
allowing comprehensive screening in a single visit. Clinical
outcomes were assessed by postprocedure physician and
patient questionnaires.
RESULTS: Two hundred thirty-five patients were random-
ized (control 5 121, conversion5 114). In the control
group, 28% had an indication for colonoscopy. Three of 33
(9%) with an abnormal sigmoidoscopy did not return for
colonoscopy. At colonoscopy, 27% had a proximal ade-
noma. In the conversion group, 28% had an abnormal sig-
moidoscopy and underwent conversion to colonoscopy.
Forty-one percent undergoing colonoscopy in the conver-
sion group had a proximal adenoma. Physicians reported no
differences in preparation or procedure difficulty, whereas
patients reported no differences in the level of comfort or
overall satisfaction between groups. When queried regard-
ing preferences for future screening, 96% chose the conver-
sion strategy.
CONCLUSIONS: The conversion strategy led to similar out-
comes compared to traditional screening while improving
compliance with colonoscopy in patients with an abnormal
sigmoidoscopy. (Am J Gastroenterol 2000;95:2074–2079.
© 2000 by Am. Coll. of Gastroenterology)
INTRODUCTION
Colon cancer is the third-leading cause of cancer mortality
in men and the third-leading cause of cancer mortality in
women within the U.S., but the second leading cause of
death nationally (1). It has been estimated that the cumula-
tive lifetime risk of developing colon cancer is approxi-
mately 5% (1).
Screening for colon cancer with annual fecal occult blood
testing and/or flexible sigmoidoscopy leads to the detection
of earlier stage tumors and decreases colon cancer mortality
(2, 3). Colon cancer screening has recently been endorsed by
a consortium of medical societies including the American
Cancer Society and the American Gastroenterological As-
sociation (2). Although this consortium supported five dif-
ferent screening strategies, randomized, controlled trial data
exist for only annual fecal occult blood testing (4–9). Case
control studies suggest that flexible sigmoidoscopy every 5
years may also reduce colon cancer mortality (10). As the
guideline supported five different strategies, it is clear that
the optimal means of screening for colorectal cancer has yet
to be determined.
At the Ann Arbor Veterans Affairs Medical Center, all
patients referred for screening flexible sigmoidoscopy are
prepared with a buffered oral phosphate solution. The qual-
ity of preparation achieved by this method is similar to that
of the more traditional colonoscopy preparation with poly-
ethylene glycol (PEG) (11) and, in our anecdotal experi-
ence, superior to enema preparation. In addition, all sig-
moidoscopies are performed with a colonoscope. We have
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recently reported the feasibility of converting screening
sigmoidoscopy to full colonoscopy in selected patients (12).
This so-called “conversion” strategy allows comprehensive
colorectal cancer screening in a single visit.
We performed a randomized, controlled trial to assess the
feasibility as well as technical and clinical outcomes of
converting sigmoidoscopy to colonoscopy in selected pa-
tients in a single visitversus traditional screening with




From November 1997 until June 1998, consecutive average-
risk patients referred from the General Medicine and Gas-
troenterology outpatient clinics for colorectal cancer screen-
ing with sigmoidoscopy were recruited from the Department
of Veteran’s Affairs Medical Center (VAMC) in Ann Arbor,
Michigan. This protocol was approved by the Ann Arbor
VAMC ethics committee. All patients were.50 yr of age
and able to understand and provide written informed con-
sent. Patients with indications for immediate colonoscopy
including gastrointestinal bleeding, weight loss, inflamma-
tory bowel disease, family history of familial adenomatous
polyposis, or colon cancer were not eligible. In addition,
patients taking warfarin for any reason were not enrolled.
Because we used preparation with oral phosphate solution,
patients with a creatinine.3 mg/dl or a history of conges-
tive heart failure were not eligible for the protocol.
Study Protocol
At the time sigmoidoscopy was ordered, patients were of-
fered participation and randomized by calendar day to one
of two arms, as described below. Both study arms under-
went flexible sigmoidoscopy using a colonoscope. All pro-
cedures were performed by or under the supervision of a
faculty member in the Division of Gastroenterology at the
University of Michigan Medical Center using state-of-the-
art videoendoscopy equipment (Olympus Corporation,
Melville, NY). A schematic of the study protocol is outlined
in Figure 1A, B.
CONTROL GROUP. The control group underwent tradi-
tional colon cancer screening with flexible sigmoidoscopy.
Sigmoidoscopy preparation at the Ann Arbor VAMC con-
sists of two doses of oral Fleets phospho-soda buffered
saline laxative (CB Fleet Co, Inc, Lynchburg, VA). Patients
were instructed to mix 1.5 oz of Fleets phospho-soda with 4
oz of water to be taken at 4 pm and again at 8 pm on the day
before the procedure. At least three 8-oz portions of clear
liquids were taken after each dose. Small amounts of clear
liquids were allowed until 2 h before the procedure.
On the day of the procedure, patients underwent sigmoid-
oscopy to 60 cm or the level of the splenic flexure. Patients
with a normal examination were told to arrange for a repeat
sigmoidoscopy in 5 yr. Any polyp.5 mm in diameter or
multiple diminutive polyps were cold biopsied. For both
arms of the study, polyp size was assessed relative to an
open standard biopsy forcep. If examination of the polyp
demonstrated hyperplastic or normal histology, the patient
was told to arrange for a repeat flexible sigmoidoscopy in 5
yr. If histopathological examination revealed the polyp or
polyps to be adenomatous, arrangements were made for full
colonoscopy at a later date. Patients were notified of the
need for colonoscopy by phone and in writing. Colonoscopy
was scheduled within 30 days of the sigmoidoscopy. The
Figure 1. Management flow diagram of patients randomized to the control (A) or conversion (B) groups.
2075AJG – August, 2000 The Conversion Strategy
number of patients who ultimately did not return for
colonoscopy was recorded.
Preparation for colonoscopy consisted of oral PEG
(Golytely, Braintree Laboratories, Inc, Braintree, MA),
which was taken starting at 2 pm on the day before the
procedure. Eight-ounce aliquots of PEG were taken every
30 min until the fecal effluent was clear or until a total of 4
L was consumed. Small amounts of clear liquids were
allowed thereafter until 2 h before colonoscopy.
CONVERSION GROUP. Patients were prepared for the
procedure with two doses of oral Fleets phospho-soda buff-
ered saline laxative as described above. Before their proce-
dure, patients provided informed consent for the conversion
strategy. This informed consent included a full description
of the possible need for colonoscopy. If examination to 60
cm or the splenic flexure was normal, the procedure was
discontinued and the patient was instructed to schedule a
follow-up sigmoidoscopy in 5 yr. If a polyp of.5 mm in
diameter or multiple diminutive polyps were seen, full
colonoscopy was performed during the same visit. Intrave-
nous access (IV) was established at the time the decision
was made to proceed with colonoscopy. IV sedation with
diazepam and meperidine were administered as necessary to
facilitate a complete examination of the colon. Any polyps
identified were hot biopsied (Endostat II, Microvasive,
Natick, MA) and separated into those obtained in the distal
60 cm of the colon and those taken more proximally. Polyps
were evaluated by a VAMC pathologist blinded to the study.
PHYSICIAN ASSESSMENTS. After each procedure, phy-
sicians filled out a questionnaire that assessed the extent of
the procedure, number and size of any polyps identified,
quality of the preparation, and difficulty of the procedure.
Quality of preparation was assessed using a 4-point Likert
scale and difficulty of procedure was assessed using a
3-point Likert scale.
PATIENT ASSESSMENTS. After completing each endo-
scopic procedure, patients evaluated their experience with a
questionnaire that assessed comfort and overall satisfaction.
These outcomes were assessed using a 4-point Likert scale.
Patients in the control group who underwent both sigmoid-
oscopy with the Fleets phospho-soda preparation and
colonoscopy with the PEG preparation were questioned
regarding which preparation they preferred. Patients’ pref-
erences were also determined for a hypothetical situation
describing colorectal cancer screening as performed in the
control versusconversion groups (Appendix 1).
Statistics
Physician and patient assessments between groups were
compared using the Z-test for proportions with Yates cor-
rection for continuity. Ap value of,0.05 defined a statis-
tically significant difference between the control and con-
version groups.
RESULTS
Two hundred thirty-five patients (227 men, 8 women) were
randomized to the control (n5 121) or conversion (n5
114) groups. The control and conversion groups were com-
parable with regard to gender distribution, age, and ethnic
composition. Seventy-one percent of patients were referred
from the General Medicine clinic and 29% from the Gas-
troenterology clinic. Clinical outcomes, and physician and
patient assessments are provided in Table 1.
Control Group
One patient (1%) in the control group refused to participate.
During sigmoidoscopy, 33/120 (28%) in the control group
had an indication for colonoscopy (Table 1). Five of 120
(4%) patients had only hyperplastic polyps during sigmoid-
oscopy. Of the 33 patients with at least one adenomatous
polyp by sigmoidoscopy, three (9%) patients did not return
for colonoscopy. Of the patients who returned for colonos-
copy, 100% achieved intubation of the cecum. Eight of 30
(27%) patients who underwent colonoscopy were found to
have proximal adenomatous polyps. No colonic malignan-
cies were identified in the control group.
Conversion Group
Nine of 114 patients (8%) randomized to the conversion
group did not complete the study. One patient refused en-
rollment after being informed of the protocol. Six patients
did not bring a driver to their appointment. Two patients
randomized to the conversion arm were disqualified from
the study when the endoscopist on duty mistakenly per-
formed routine screening with sigmoidoscopy alone rather
than the conversion strategy. Both patients had adenomatous
polyps on sigmoidoscopy, which were managed with
colonoscopy on a different day.
Twenty-nine of 105 (28%) patients in the conversion
group had an indication for colonoscopy (Table 1). All
patients who were converted to colonoscopy achieved suc-




Randomized 121 114 NS
Completed study 117 105 NS
Adenomas by FS 33 (28%)* 29 (28%) NS
Proximal adenomas by
colonoscopy




21/30 (70%) 20/29 (69%) NS
Procedure difficulty
(difficult)




22/30 (73%) 19/29 (66%) NS
Overall satisfaction
(good or excellent)
26/30 (86%) 23/29 (79%) NS
* Three patients in the control group did not return for colonoscopy
NS 5 not significant; FS5 flexible sigmoidoscopy.
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cessful intubation of the cecum. Twelve of 29 (41%) pa-
tients who underwent conversion to colonoscopy were
found to have more proximal adenomas. Four patients
(14%) in the conversion group underwent colonoscopy
based upon left colon polyp/polyps ultimately found to be
hyperplastic by histology. Of these four patients, two were
found to have a more proximal adenomatous polyp, includ-
ing one tubulovillous adenoma, by colonoscopy. No carci-
nomas were found in the conversion group.
Physician Assessments
The quality of colonoscopy preparation was assessed for
those receiving PEG in the control group and oral Fleets
phospho-soda in the conversion group. Preparation was
rated as good or excellent in 21/30 (70%) of the control
group versus20/29 (69%) of the conversion group (NS).
Two patients in each group were believed to have an inad-
equate preparation during colonoscopy. All four patients
eventually underwent successful colonoscopy at a later date.
We acknowledge that the design of our protocol made it
difficult to blind endoscopists to the method of preparation
used for colonoscopy. Physicians assessed difficulty of the
procedure as difficult in 2/30 (6%) in the control group
versus3/29 (10%) in the conversion group (NS).
Patient Assessments
Patient assessments of comfort during colonoscopy between
the study groups were comparable. Twenty-two of 30 (73%)
patients in the control group and 19/29 (66%) in the conversion
group rated their comfort level as good or excellent (NS).
Overall satisfaction with the screening process was rated as
good or excellent in 26/30 (86%) patients in the control group
and 23/29 (79%) patients in the conversion group (NS).
Patients in the control group who were prepared for
sigmoidoscopy with oral Fleets phospho-soda and colonos-
copy with PEG overwhelmingly preferred the oral Fleets
phospho-soda preparation (n5 30, 73%vs14%,p 5 0.01).
After their screening procedure, all patients in the control
and conversion groups were asked which screening program
they would prefer in the future: traditional screening with
sigmoidoscopy and, where appropriate, colonoscopy on a
separate day, or the conversion strategy in a single visit
(Appendix 1). Despite being told that all participants would
need a driver and that there was only a 1/3 chance that
conversion to colonoscopy would be necessary, 96% pre-
ferred the conversion strategy (n5 222, p 5 0.001). It is
noteworthy that 40% of patients in the control group brought
a driver or companion to their appointment for sigmoidos-
copy.
DISCUSSION
Screening for colorectal cancer by means of fecal occult
blood testing and/or sigmoidoscopy is achieving widespread
acceptance. Unfortunately, fecal occult blood testing is nei-
ther sensitive nor specific for colorectal neoplasia (13).
Flexible sigmoidoscopy is more specific but does not detect
all patients with adenomatous polyps or malignancy (2). Of
the five proposed screening strategies, four require an ad-
ditional visit for colonoscopy if an abnormality is identified
during the first phase of the screening process. Associated
with a second visit are the need for another preparation, loss
of time from work, the small but definable associated risk,
and the monetary cost of an additional procedure.
Of the five recommended screening strategies, only
colonoscopy every 10 yr allows for comprehensive diag-
nostic and therapeutic intervention in a single visit. Al-
though few would disagree that colonoscopy is the optimal
means by which to screen for colon cancer, this strategy is
arguably the least commonly implemented in clinical prac-
tice. Issues delaying the widespread acceptance of screening
colonoscopy include high up-front costs, limited accessibil-
ity, inadequate manpower, the lack of clinical trials to sup-
port the cost-effectiveness of such a strategy, and a lack of
familiarity by primary care physicians with this strategy as
a screening option.
Recognizing the limitations of the currently available
methods of screening for colorectal cancer, we evaluated a
novel strategy consisting of converting sigmoidoscopy to
colonoscopy in those with a single polyp.5 mm in diam-
eter or multiple diminutive polyps. Our criteria for convert-
ing sigmoidoscopy to colonoscopy were based upon several
observations from the literature. The size of an adenomatous
polyp has been found to be an independent risk factor for the
presence of colonic malignancy. Polyps,5 mm in diameter
have a,1% likelihood of containing high-grade dysplasia.
In contrast, polyps.1 cm have a 21% chance of containing
high-grade dysplasia (14). The size of an adenoma also
predicts the likelihood of having additional adenomas or
malignancy elsewhere in the colon (15). Other factors associ-
ated with colonic malignancy include villous histology and the
presence of multiple polyps (14–16). Several recent studies
have supported performing colonoscopy in patients found to
have even diminutive distal colonic adenomas (17, 18).
By preparing patients scheduled for sigmoidoscopy with
oral Fleets phospho-soda and performing screening proce-
dures with a colonoscope, the conversion strategy proved
technically feasible. The technical and clinical outcomes
measured between the study groups were similar. All pa-
tients with an indication for colonoscopy underwent suc-
cessful intubation of the cecum. As others have previously
reported (11), we found that the quality of preparation for
colonoscopy with Fleets phospho-soda was comparable to
PEG. Two patients in each group were believed to be
inadequately prepared for their procedure and required a
follow-up colonoscopy. Although the quality of preparation
was equivalent, patients who received both preparations
preferred oral Fleets phospho-soda over PEG. We did not
formally evaluate patient preferences for sigmoidoscopy
preparation with enemasversusoral Fleets phospho-soda in
this study. However, we did informally survey preferences
of study patients who had prepared for a previous sigmoid-
oscopy with enemas. Overwhelmingly, patients preferred
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the oral Fleets phospho-soda over enemas. In addition, pa-
tients reported no significant difference in the level of dis-
comfort or overall satisfaction between the two study arms.
We believe that the conversion strategy improves upon
traditional screening with fecal occult blood testing and/or
sigmoidoscopy by providing comprehensive evaluation and
intervention in a single visit. In our study, 3/33 (9%) patients
in the control group with an adenoma by sigmoidoscopy did
not return for colonoscopy. Other studies have reported that
as many as 25% of patients with a positive fecal occult
blood test or abnormal sigmoidoscopy do not comply with
colonoscopy (5, 19). If a patient with an abnormal screening
test fails to undergo colonoscopy and develops a colorectal
cancer, the effort and resources committed to the screening
enterprise will have been wasted. In addition, the conversion
strategy limits colonoscopy to only those with an abnormal
sigmoidoscopy. As such, it is conceivable that this strategy
could limit the number of colonoscopies performed in pa-
tients with no colonic neoplasia, a point worthy of consid-
eration in this age of limited health care resources.
There are several potential limitations associated with the
widespread adoption of the conversion strategy. As the
endoscopist does not know whether a patient will require
sigmoidoscopy or colonoscopy before the procedure, sched-
uling conflicts are likely to arise with the conversion strat-
egy. After discussions between the investigators and partic-
ipating endoscopists, we have estimated that converting to
colonoscopy takes approximately 15–20 min longer than a
standard sigmoidoscopy alone. We acknowledge that this is
only our best estimate as no formal evaluation in this regard
was performed. This incremental increase in procedure time
is accounted for by placement of an IV catheter for con-
scious sedation and the additional time required to evaluate
the transverse and ascending colon. It is worth noting that a
small number of patients did not require placement of an IV
catheter for sedation. The feasibility of unsedated colonos-
copy has recently been reported by several groups (20, 21).
Certainly, for a high-volume endoscopy practice, this in-
crease in procedure time could prove problematic. However,
if an endoscopist schedules two to three sigmoidoscopies
per day and approximately one-third require conversion
from sigmoidoscopy to colonoscopy, the incremental in-
crease in time should prove to be minimal. In addition,
endoscopists will ultimately save time using the conversion
strategy, as patients with a polyp will require one rather than
two procedures. By streamlining the screening process, the
conversion strategy may provide a means of dealing with the
growing number of sigmoidoscopies ordered by primary
care physicians.
In addition, the conversion strategy does lead to colonos-
copy in a percentage of patients with only hyperplastic
polyps by sigmoidoscopy. The literature would suggest that
patients with distal hyperplastic polyps should not undergo
colonoscopy given their minimal risk of harboring more
proximal neoplastic lesions (2). In our study, 4/29 (14%)
patients who underwent conversion of sigmoidoscopy to
colonoscopy were ultimately found to have only hyperplas-
tic polyps in the left colon. Interestingly, 2/4 patients were
found to have at least one adenoma (including a tubulovil-
lous adenoma) in the proximal colon.
We wondered whether the conversion strategy would be
acceptable from a patient’s perspective, as only one-third
would receive conscious sedation yet all would require a
driver for their procedure. In addition to the associated
inconvenience, this could lead to indirect expenses associ-
ated with lost time from work for the driver. This proved to
be a relevant concern, as 6/114 (5%) patients in the con-
version arm did not bring a driver and had to be disqualified
from the study. These patients were managed with sigmoid-
oscopy and, when indicated, colonoscopy on a different day.
An interesting observation from our study was that 40% of
patients in the control group brought a driver or companion
to their appointment for sigmoidoscopy despite being told
that this would not be necessary. When patients in both
groups were asked which screening program they would
prefer in the future (traditional screening with sigmoidos-
copy and, where appropriate, colonoscopy on a separate day
or the conversion strategy in a single visit), 96% preferred
the conversion strategy (p 5 0.001). We acknowledge that
surveys such as this are subject to bias based upon the
manner in which it is written and prior patient experiences.
Because of these concerns, we purposely excluded any
mention of the preparation for traditional screening or the
conversion strategy from this survey in the hopes of limiting
bias based upon a particular patient’s previous experiences.
In addition, only 30 control group patients found to have a
polyp by sigmoidoscopy received oral phospho-soda for
sigmoidoscopy and PEG preparation for colonoscopy.
Eighty-five percent of the patients surveyed received only
oral phospho-soda before their procedure, further limiting
the chance of bias associated with the preparation.
The most difficult issue to deal with regarding the con-
version strategy is that of reimbursement. This was not an
issue in the VA patient population utilized for this study.
However, this is certainly an issue that will need to be
considered and reconciled before implementation of the
conversion strategy in a non-VA patient population. In our
opinion, it would be reasonable to bill for a sigmoidoscopy
when procedures are not converted to colonoscopy. In cases
requiring conversion of sigmoidoscopy to colonoscopy, bill-
ing for colonoscopy would seem appropriate. From a pay-
or’s perspective, the conversion strategy should be quite
attractive given the significant savings associated with the
elimination of charges for sigmoidoscopy in as many as
one-third of patients.
In conclusion, we have shown that the conversion strat-
egy is technically feasible and leads to similar clinical
outcomes compared to traditional screening with sigmoid-
oscopy. From the patient’s perspective, comprehensive
colorectal cancer screening can be achieved in a single visit.
From the physician’s perspective, the conversion strategy
leads to improved compliance with colonoscopy in patients
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with an abnormal sigmoidoscopy. From the payor’s per-
spective, this strategy should decrease overall costs associ-
ated with colorectal cancer screening by eliminating charges
associated with sigmoidoscopy in as many as one-third of
patients. For a number of practical reasons, the conversion
strategy will not be appropriate for all patients to be
screened for colorectal cancer. However, the conversion
strategy should be considered as another viable colorectal
screening option. Studies to confirm the applicability of the
conversion strategy to a community-based setting are cur-
rently in progress.
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APPENDIX 1
Choices for Colon Cancer Screening
Which of the following choices of colon cancer screening
would you prefer:
A. Sigmoidoscopy, which consists of passing a tube which
we can view through, only a short distance into the colon
without medication to sedate you. As no sedation is
given, you will not need a driver for the sigmoidoscopy.
If an abnormal growth is seen, it will be biopsied at the
time of this procedure. If the biopsy shows a precancer-
ous growth (1/3 chance), you will require a full exam-
ination of the colon on adifferent day. Medications to
make you comfortable will be given for the full exam-
ination of the colon. Because of this, you will need a
driver for your second appointment.
B. Sigmoidoscopy is performed as outlined above. If a
polyp or abnormal growth is identified, an intravenous
catheter will be placed and medications will be given to
make you comfortable. A full examination of the colon
will then be performed during thesame visit. This will
require that you bring a driver to your appointment.
There is a greater chance that a full examination of the
colon will be performed using this strategy.
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